Our News
May 20, 2025
2024 was a strong year for Alnylam with significant milestones achieved, including the readout of the pivotal HELIOS-B study along with steady progress across our expanding pipeline. As our company has continued to grow, so too have our corporate responsibility (CR) efforts.
As we continue to lead the way in RNAi innovation, there is a profound opportunity in front of us to shape the future of medicine and impact the lives of millions of patients. At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all.” - Yvonne Greenstreet, MD, Chief Executive Officer of Alnylam
With the release of our 2024 Corporate Responsibility Report, we demonstrate the increasing sophistication of our CR efforts in line with company growth and stakeholder expectations. Our theme “Accepting Challenges to Improve the Health of Humanity" continues to guide our CR strategy, which is integrated into our business through interconnected pillars that inform our work – Patients, Science, Employees, Communities, Planet, and Governance.
Highlights from this year’s report include:
We’re proud of our achievements this year and extend our deepest gratitude to our employees and our external partners for their valued contributions to this work.
We invite you to download our 2024 Corporate Responsibility Report to read more about our efforts and progress.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site